上海醫藥(601607.SH)：I039獲得臨牀試驗批准通知書

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

上海醫藥(601607.SH)：I039獲得臨牀試驗批准通知書

格隆匯 07-27 16:24

格隆匯7月27日丨上海醫藥(601607.SH)公佈，公司自主研發的“I039”(以下或稱“該項目”)收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》，將於近期啟動國內Ⅰ期臨牀試驗。I039是一款腸道限制性的免疫調節劑，能抑制胃腸道的炎症反應和激活胃腸道的調節反應。臨牀前研究顯示I039能改善腸炎動物模型的腸道炎症的症狀。該項目由上海醫藥集團股份有限公司自主研發，上海醫藥集團股份有限公司擁有完全知識產權。

上海醫藥(02607.HK)

Relevant Stocks

上海醫藥(02607.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

上海醫藥(601607.SH)：I039獲得臨牀試驗批准通知書

Services

About Us

Agreement Statement